跳转至内容
Merck
CN

D2920000

丙吡胺

European Pharmacopoeia (EP) Reference Standard

别名:

双异丙吡胺

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C21H29N3O
化学文摘社编号:
分子量:
339.47
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI

1S/C21H29N3O/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25)

SMILES string

CC(C)N(CCC(C(N)=O)(c1ccccc1)c2ccccn2)C(C)C

InChI key

UVTNFZQICZKOEM-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

disopyramide

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Disopyramide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

IA 类抗心律失常药;钠通道阻断剂

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

pictograms

Health hazardExclamation mark

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Repr. 2

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

J P Fauchier et al.
Archives des maladies du coeur et des vaisseaux, 84(4), 553-560 (1991-04-01)
Moricizine chlorhydrate (Ethmozine), a relatively unknown antiarrhythmic agent in France, is a derivative of Phenothiazine, related to the Vaughan-Williams Class IB drugs. A randomised, double-blind, crossover trial with Disopyramide 600 mg/day after a placebo period in 10 patients with ventricular
Procainamide and disopyramide.
C Ribeiro et al.
European heart journal, 8 Suppl A, 11-19 (1987-03-01)
Pharmacokinetics and pharmacodynamics of disopyramide.
J Bonde
Danish medical bulletin, 38(2), 121-133 (1991-04-01)
T Tokudome et al.
Angiology, 50(4), 331-335 (1999-05-04)
The effect of intravenous administration of disopyramide (total dose 100 mg, bolus 20 mg every 5 minutes) was compared with that of propranolol (total dose 10 mg, bolus 2 mg every 5 minutes) in a patient with hypertrophic obstructive cardiomyopathy.
M S Croxson et al.
The New Zealand medical journal, 100(827), 407-408 (1987-07-08)
A patient treated with disopyramide presented with hypoglycaemia, a raised serum insulin level and died of pneumonia. From these findings and a review of 10 case reports, we propose that disopyramide causes hypoglycaemia by stimulation of insulin release as described

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持